Order Article Reprints

Stukan I, Gryzik M, Hoser G, Want A, Grabowska-Pyrzewicz W, Zdioruk M, Napiórkowska M, Cieślak M, Królewska-Golińska K, Nawrot B, et al. Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34⁺/CD38⁻ Leukemia Stem Cells. Cancers. 2022; 14(15):3641. https://doi.org/10.3390/cancers14153641

Stukan, Iga, Marek Gryzik, Grażyna Hoser, Andrew Want, Wioleta Grabowska-Pyrzewicz, Mikolaj Zdioruk, Mariola Napiórkowska, Marcin Cieślak, Karolina Królewska-Golińska, Barbara Nawrot, and et al. 2022. "Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34⁺/CD38⁻ Leukemia Stem Cells" Cancers 14, no. 15: 3641. https://doi.org/10.3390/cancers14153641

Stukan, I., Gryzik, M., Hoser, G., Want, A., Grabowska-Pyrzewicz, W., Zdioruk, M., Napiórkowska, M., Cieślak, M., Królewska-Golińska, K., Nawrot, B., Basak, G., & Wojda, U. (2022). Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34⁺/CD38⁻ Leukemia Stem Cells. Cancers, 14(15), 3641. https://doi.org/10.3390/cancers14153641